Globus Medical, Inc. (GMED) P/E Ratio History
Historical price-to-earnings valuation from 2012 to 2025
Loading P/E history...
GMED Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 6, 2026, Globus Medical, Inc. (GMED) trades at a price-to-earnings ratio of 23.0x, with a stock price of $90.03 and trailing twelve-month earnings per share of $3.92.
The current P/E is 60% below its 5-year average of 57.3x. Over the past five years, GMED's P/E has ranged from a low of 18.5x to a high of 231.3x, placing the current valuation at the 15th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.2x, GMED is roughly in line with its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 171.0x.
The PEG ratio of 0.74 (P/E divided by 423% EPS growth) suggests the stock may be undervalued relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, GMED trades roughly in line with the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GMED DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
GMED P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $113B | 35.1 | 2.36Best | +8% | |
| $16B | 23.4 | - | -20% | |
| $100B | 21.5Lowest | - | +31% | |
| $83B | 28.9 | - | +55%Best | |
| $17B | 30.5 | - | -25% | |
| $160B | 57.4 | 2.64 | +23% | |
| $4B | 28.4 | - | +5% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
GMED Historical P/E Data (2012–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $87.31 | $3.92 | 22.3x | -45% |
| FY2025 Q3 | $57.27 | $3.10 | 18.5x | -54% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $59.02 | $2.60 | 22.7x | -43% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $73.20 | $1.34 | 54.6x | +36% |
| FY2024 Q4 | $82.71 | $0.75 | 110.7x | +176% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $71.54 | $0.67 | 107.2x | +167% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $68.49 | $0.30 | 231.3x | +476% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $53.64 | $0.64 | 84.3x | +110% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $53.29 | $1.17 | 45.6x | +14% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $49.65 | $1.55 | 32.1x | -20% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $59.54 | $2.01 | 29.6x | -26% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $56.64 | $1.97 | 28.8x | -28% |
Average P/E for displayed period: 40.2x
Full GMED Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See GMED's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GMED Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GMED vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGMED — Frequently Asked Questions
Quick answers to the most common questions about buying GMED stock.
Is GMED stock overvalued or undervalued?
GMED trades at 23.0x P/E, below its 5-year average of 57.3x. At the 15th percentile of historical range, the stock is priced at a discount to its own history.
How does GMED's valuation compare to peers?
Globus Medical, Inc. P/E of 23.0x compares to sector median of 22.2x. The premium reflects expected growth above peers.
What is GMED's PEG ratio?
GMED PEG ratio is 0.74. Below 1.0 indicates valuation is supported by earnings growth rate. Historical P/E data spans 2012-2025.